Preparation and study of chiral boron containing amine-cyano(pyrrolyl-1)borane complexes. Preparation of (−)-(S)-α-phenylethylamine-(−)-cyano(pyrrolyl-1)borane and (+)-(R)-α-phenylethylamine-(+)-cyano(pyrrolyl-1)borane
作者:Bëla Györi、József Emri
DOI:10.1016/s0022-328x(00)84799-3
日期:1982.10
Several amine-cyano(pyrrolyl)boranecomplexes [A · BH(NC4H4)CN] containing a chiral boron atom were prepared from the reactions of sodium cyanohydrodipyrrolylborate-tridioxane1 [NaBH(NC4H4)2CN · 3C4H8O2] with amine hydrochlorides as well as by base exchange from the appropriate 4-cyanopyridine complex [4-CNC5H4N · BH(NC4H4)CN]. Amines with an sp2 N atom give stable complexes of a wide range of basicity
若干胺氰基(吡咯基)硼烷配合物[A·BH(NC 4 H ^ 4)CN]含有手性硼原子被选自钠cyanohydrodipyrrolylborate-tridioxane的反应制备1 [加入NaBH(NC 4 H ^ 4)2 CN·3C 4 H 8 O 2 ]与胺盐酸盐以及通过从适当的4-氰基吡啶络合物[4-CNC 5 H 4 N·BH(NC 4 H 4)CN]进行碱交换。带有sp 2 N原子的胺可提供多种碱度的稳定络合物(p K a= 0.8-9.7),与sp 3杂化N的胺类相反,后者只有更强的碱(p K a 7.3 7.3)才能产生稳定的络合物(主要是仲胺和叔胺)。这些化合物在中性和碱性介质中会发生水解,而在强酸中,它们会通过在吡咯基的α-C原子上质子化产生稳定的硼离子。化合物(-)-(S)-α-苯乙胺-(-)-氰基吡咯烷硼烷和(+)-(R)-α-苯乙胺-(+)-氰基吡咯烷硼烷已制备成纯净
Direct Arylation of N-Heteroarenes with Aryldiazonium Salts by Photoredox Catalysis in Water
solvent, an array of xanthenes, thiazole, pyrazine, and pyridazine are compatible with this new arylation approach. The broad substrate scope, mild reaction conditions, and use of water as reaction solvent make this procedure a practical and environmentally friendly method for the synthesis of compounds containing aryl‐heteroaryl motifs.
已经开发出一种高效的可见光促进的N-杂芳烃与芳基重氮盐在水中的“自由基型”偶联。在室温下将反应继续进行的[Ru(联吡啶)3 ]氯2 ⋅ 6 H 2O作为光敏剂,商用灯泡作为光源。在这些反应条件下,吡啶和各种取代的吡啶是有效的底物,仅形成具有不同区域选择性的单取代产物。使用甲酸水溶液作为溶剂,一系列的黄嘌呤,噻唑,吡嗪和哒嗪与这种新的芳基化方法兼容。广泛的底物范围,温和的反应条件以及使用水作为反应溶剂,使得该程序成为合成具有芳基-杂芳基基序的化合物的实用且环境友好的方法。
The present invention is directed to 2-pyridyloxy-3-substituted-4-nitrile compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-3-substituted-4-nitrile compounds described herein in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.